Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADCY5 | O95622 | 5/20 | 0.63 |
| ▸ | ADORA2A | P29274 | 7/20 | 0.61 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.61 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.61 |
| ▸ | NSD3 | Q9BZ95 | 1/20 | 0.56 |
| ▸ | PI4KA | P42356 | 2/20 | 0.56 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.56 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.56 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.56 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.55 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | AHCY | P23526 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6045668 | 0.91 | ADCY5 (0.72) | ADCY5ADORA2AADORA1ADORA2BNSD3 | |
| SCHEMBL6045687 | 0.87 | EP300 (0.62) | ADCY5ADORA2AADORA1ADORA2BNSD3 | |
| SCHEMBL6694591 | 0.86 | EGFR (0.60) | ADCY5ADORA2AADORA1ADORA2BPI4KA | |
| SCHEMBL14113709 | 0.86 | ADORA2A (0.57) | ADCY5ADORA2AADORA1ADORA2BNSD3 | |
| SCHEMBL13882135 | 0.85 | ADORA2A (0.66) | ADCY5ADORA2AADORA1ADORA2BPI4KA | |
| SCHEMBL9534919 | 0.84 | P2RX7 (0.51) | ADCY5FGFR1 | |
| SCHEMBL983769 | 0.83 | ADORA2A (0.68) | ADCY5ADORA2AADORA1ADORA2BPI4KA | |
| SCHEMBL12922450 | 0.82 | ADORA2A (0.67) | ADCY5ADORA2AADORA1ADORA2BPI4KA | |
| SCHEMBL6045601 | 0.82 | ADCY5 (0.85) | ADCY5ADORA2AADORA1ADORA2BPI4KA | |
| SCHEMBL12948654 | 0.81 | ADORA2A (0.68) | ADCY5ADORA2AADORA1ADORA2BPI4KA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115478086-A | Method for enzymatic on-line synthesis of adenine Michael addition derivatives | 浙江工业大学 | 2022-12-16 | — | — | CN | disclosed |
| EP-1613628-B1 | REVERSIBLE INHIBITORS OF S-ADENOSYL-L-HOMOCYSTEINE HYDROLASE AND USES THEREOF | GEN ATOMICS (US) | 2013-11-20 | — | — | EP | disclosed |
| EP-1799682-B1 | REVERSIBLE INHIBITORS OF S-ADENOSYL-L-HOMOCYSTEINE HYDROLASE AND USES THEREOF | GEN ATOMICS (US) | 2012-12-05 | — | — | EP | disclosed |
| US-8168643-B2 | Multiple sclerosis; hemorrhagic virus infection, autoimmune diseases, autograft rejection, neoplasm, hyperhomocysteineuria, cardiovascular disease, stroke, Alzheimer's disease, or diabetes; can be used in combination with an anti-hemorrhagic viral infection agent, immunosuppressant | GENERAL ATOMICS (US) | 2012-05-01 | — | — | US | disclosed |
| US-7868011-B2 | Use of reversible inhibitors of S-adenosyl-L-homocysteine hydrolase for treating lupus | GENERAL ATOMICS (US) | 2011-01-11 | — | — | US | disclosed |
| US-7517887-B2 | Reversible inhibitors of S-adenosyl-L-homocysteine hydrolase and uses thereof | GENERAL ATOMICS (US) | 2009-04-14 | — | — | US | disclosed |
| US-20080194594-A1 | Use of reversible inhibitors of s-adenosyl-l-homocysteine hydrolase for treating lupus | NINGBO ZIYUAN PHARMACEUTICALS, INC. (CN) | 2008-08-14 | — | — | US | disclosed |
| US-20080171049-A1 | Reversible inhibitors of S-adenosyl-L-homocysteine hydrolase and uses thereof | NINGBO ZIYUAN PHARMACEUTICALS, INC. (CN) | 2008-07-17 | — | — | US | disclosed |
| WO-2008086203-A1 | USE OF REVERSIBLE INHIBITORS OF S-ADENOSYL-L-HOMOCYSTEINE HYDROLASE FOR TREATING LUPUS | GENERAL ATOMICS (US) | 2008-07-17 | — | — | WO | disclosed |
| US-20070207172-A1 | Use of reversible inhibitors of S-adenosyl-L-homocysteine hydrolase for treating lupus | NINGBO ZIYUAN PHARMACEUTICALS, INC. (CN) | 2007-09-06 | — | — | US | disclosed |
| US-20070129386-A1 | Reversible inhibitors of S-adenosyl-L-homocysteine hydrolase and uses thereof | NINGBO ZIYUAN PHARMACEUTICALS, INC. (CN) | 2007-06-07 | — | — | US | disclosed |
| US-7196093-B2 | Reversible inhibitors of SAH hydrolase and uses thereof | GENERAL ATOMICS (US) | 2007-03-27 | — | — | US | disclosed |
| US-20050182075-A1 | Reversible inhibitors of S-adenosyl-L-homocysteine hydrolase and uses thereof | NINGBO ZIYUAN PHARMACEUTICALS, INC. (CN) | 2005-08-18 | — | — | US | disclosed |
| US-6887880-B2 | Adenine based inhibitors of adenylyl cyclase, pharmaceutical compositions, and method of use thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-05-03 | — | — | US | disclosed |
| US-20040204429-A1 | Reversible inhibitors of SAH hydrolase and uses thereof | NINGBO ZIYUAN PHARMACEUTICALS, INC. (CN) | 2004-10-14 | — | — | US | disclosed |
| US-20020068745-A1 | Adenine based inhibitors of adenylyl cyclase, pharmaceutical compositions, and method of use thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2002-06-06 | — | — | US | disclosed |
| WO-2002040481-A2 | ADENINE BASED INHIBITORS OF ADENYLYL CYCLASE, PHARMACEUTICAL COMPOSITIONS AND METHOD OF USE THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2002-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040204429-A1 | Reversible inhibitors of SAH hydrolase and uses thereof | AHCY, BHMT, AHCYL1 | ADCY5 353/4885ADORA2A 87/4885ADORA1 93/4885 |
| US-20020068745-A1 | Adenine based inhibitors of adenylyl cyclase, pharmaceutical compositions, and method of use thereof | CD38, ADCY1, ADCY2 | ADCY5 4/4885ADORA2A 38/4885ADORA1 27/4885 |
| US-20070207172-A1 | Use of reversible inhibitors of S-adenosyl-L-homocysteine hydrolase for treating lupus | AHCY, AHCYL1, BHMT | ADCY5 448/4885ADORA2A 70/4885ADORA1 95/4885 |
| US-20080194594-A1 | Use of reversible inhibitors of s-adenosyl-l-homocysteine hydrolase for treating lupus | AHCY, AHCYL1, BHMT | ADCY5 448/4885ADORA2A 70/4885ADORA1 95/4885 |
| US-20080171049-A1 | Reversible inhibitors of S-adenosyl-L-homocysteine hydrolase and uses thereof | AHCY, AHCYL1, BHMT | ADCY5 368/4885ADORA2A 72/4885ADORA1 77/4885 |
| US-20070129386-A1 | Reversible inhibitors of S-adenosyl-L-homocysteine hydrolase and uses thereof | AHCY, AHCYL1, BHMT | ADCY5 368/4885ADORA2A 72/4885ADORA1 77/4885 |
| US-20050182075-A1 | Reversible inhibitors of S-adenosyl-L-homocysteine hydrolase and uses thereof | AHCY, AHCYL1, BHMT | ADCY5 368/4885ADORA2A 72/4885ADORA1 77/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.